AC Immune’s Mixed Phase II Results Buoy Alzheimer’s Research
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II…
An Alzheimer’s disease drug developed by AC Immune and Genentech has drawn conflicting phase II…
Bristol Myers Squibb’s recent phase III success provided the first late-stage confirmation for a novel…
While the EU saw rapid-fire approvals in the multiple sclerosis space last month, the innovations…
The success of a new drug depends on much more than its efficacy and safety…
Standardized, carefully managed samples are indispensable for the success of any clinical study. Still, sample…
The relationship between biotechs and their CRO partners has been long in the making. These…
In 2019, the global contract development and manufacturing organizations (CDMO) market was valued at about…
Developing a new drug has an estimated cost of €583M to €2.4B. Much of this…
As the complexity of drug discovery and development steadily increases, so do the costs. With…
As the region with the fastest-growing clinical activity, Asia is becoming increasingly attractive to European…
Although failure rates in drug development are still quite high, a lot can be done…
Although the exact percentage of drugs failing clinical trials is still widely disputed, the fact…